Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Announces FDA Approval of sNDA for ICLUSIG® (ponatinib) in Newly Diagnosed Ph+ ALL
Details : Iclusig (ponatinib), a Tyrosine kinase inhibitor receives Supplemental New Drug Application approval by the U.S. FDA. It is indicated for adult patients with Ph+ Acute Lymphoblastic Leukemia.
Product Name : Iclusig
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 19, 2024
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Announces FDA Approval Of sNDA for ICLUSIG® in Newly Diagnosed Ph+ ALL
Details : Iclusig (ponatinib), a kinase inhibitor, targets BCR::ABL1 for treating newly diagnosed Ph+ acute lymphoblastic leukemia in adults, in combination with chemotherapy, approved by FDA.
Product Name : Iclusig
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 19, 2024
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ICLUSIG (ponatinib) is the only pan-mutational and third-generation tyrosine kinase inhibitor (TKI), targeting BCR:ABL1 and all known single, treatment-resistant mutations, including the most resistant T315I mutation.
Product Name : Iclusig
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The updated label includes an optimized, response-based ICLUSIG dosing regimen in CP-CML with a daily starting dose of 45 mg and, upon achieving ≤1% BCR-ABL1IS, dose reduction to 15 mg.
Product Name : Iclusig
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to Chronic Phase-CML Patients with Resistance or Intolerance to At Least Two Prior Tyrosine Kinase Inhibitors. New Dosing Regimen Optimizes Benefit-Risk Profile, Providing Efficacy ...
Product Name : Iclusig
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : Ponatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the interim analysis of the Phase 2 OPTIC trial show that response-based dosing regimens of Iclusig can optimize benefit-risk profile in patients with resistant or intolerant chronic phase-chronic myeloid leukemia (CML).
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 29, 2020
Reset All
